MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today provided an update to the preliminary revenue and adjusted earnings per share growth rate guidance provided to investors at the Company’s recent analyst R&D day meeting on December 3, 2009. The Company now believes that the 2010 overall revenue percentage growth rate will be in the mid-teens and re-affirms that adjusted earnings per share will grow at 10% or more.
